Compare Gilead Sciences, Inc. (GILD) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Yum China Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $135.72 (market cap $168.35B), while Yum China Holdings Inc trades at $47.72 (market cap $16.28B). The key difference: Gilead Sciences, Inc. is far larger — about 10.3× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| GILD | YUMC | |
|---|---|---|
Market Cap | $168.35B | $16.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $57.95 |
52-Week Low | $110.56 | $40.18 |
Enterprise Value | $191.42B | $17.19B |
Dividend Yield | 2.42% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
YUMC trades at $47.77, down 0.87% today, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating estimates, and revenue growth of 13% year-over-year. Recent completion of the Pizza Hut brand acquisition in Mainland China for $1.2 billion enhances strategic control and potential margin expansion.
Outlook remains positive with consistent earnings beats and analyst consensus favoring a buy rating. Key risks include macroeconomic headwinds in China and integration challenges from the acquisition. The stock offers growth potential with a reasonable P/E of 17.43 and a projected 26.2% upside based on Wall Street targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
